Here are three quick notes:
1. Some groups opposed the 21st Century Cures Act, which loosened FDA approvals and offered NIH $8.75 billion in funding.
2. Proponents believe it will spur innovation and enhance care.
3. Opponents, however, argue the act offers an incentive for researchers to seek lawmaker endorsement of legislation that would relax drug and device approvals.
More articles on devices:
Globus Medical stock downgraded to “sell” by Goldman Sachs: 3 points
First Ray’s CortiClamp System receives FDA clearance: 4 takeaways
Stryker shares fall 0.81% — 4 notes on how the shares are faring
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
